Gene, Cell and Tissue

Published by: Kowsar

Effects of Interleukin Families Polymorphisms on Systemic Lupus Erythematosus: Focus on Interleukin-1

Maryam Moossavi 1 , 2 , Maryam Shojaee 3 , Arezoo Mollashahi 4 , Jafar Poodineh 5 , Seyedeh Zahra Moossavi 6 , Maryam Alaei 7 , Mostafa Ibrahimi 7 , * and Milad Mohammadoo Khorasani 7 , **
Authors Information
1 Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran
2 Department of Molecular Medicine, Birjand University of Medical Sciences, Birjand, Iran
3 Department of Biology, Payame Noor University of Mashhad, IR Iran
4 Department of Biology, Payame Noor University of Esfehan, IR Iran
5 Department of Clinical Biochemistry, School of Medicine, Zabol University of Medical Sciences, Zabol, IR Iran
6 Shiraz University of Medical Sciences, Shiraz, IR Iran
7 Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IR Iran
Corresponding Authors:
Article information
  • Gene, Cell and Tissue: January 2018, 5 (1); e69365
  • Published Online: January 31, 2018
  • Article Type: Review Article
  • Received: December 15, 2017
  • Revised: January 5, 2018
  • Accepted: January 15, 2018
  • DOI: 10.5812/gct.69365

To Cite: Moossavi M, Shojaee M, Mollashahi A, Poodineh J, Moossavi S Z, et al. Effects of Interleukin Families Polymorphisms on Systemic Lupus Erythematosus: Focus on Interleukin-1, Gene Cell Tissue. 2018 ; 5(1):e69365. doi: 10.5812/gct.69365.

Copyright © 2018, Gene, Cell and Tissue. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Interleukins Involved in Systemic Lupus Erythematous
3. Interleukin 1 Family
4. Interleukin 1 and SLE
5. Conclusions
  • 1. Sahebari M, Hatef MR, Rezaieyazdi Z, Abbasi M, Abbasi B, Mahmoudi M. Correlation between serum levels of soluble Fas (CD95/Apo-1) with disease activity in systemic lupus erythematosus patients in Khorasan, Iran. Arch Iran Med. 2010;13(2):135-42. [PubMed: 20187668].
  • 2. Crispin JC, Liossis SN, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med. 2010;16(2):47-57. doi: 10.1016/j.molmed.2009.12.005. [PubMed: 20138006]. [PubMed Central: PMC2823952].
  • 3. Fu SM, Deshmukh US, Gaskin F. Pathogenesis of systemic lupus erythematosus revisited 2011: end organ resistance to damage, autoantibody initiation and diversification, and HLA-DR. J Autoimmun. 2011;37(2):104-12. doi: 10.1016/j.jaut.2011.05.004. [PubMed: 21632208]. [PubMed Central: PMC3173577].
  • 4. Namazi S, Ziaee V, Rezaei N. The role of cytokines in systemic lupus erythematosis. Tehran Univ Med J. 2015;73(6):397-404.
  • 5. Murphy G, Lisnevskaia L, Isenberg D. Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment. Lancet. 2013;382(9894):809-18. doi: 10.1016/S0140-6736(13)60889-2. [PubMed: 23972423].
  • 6. Mohammadoo-Khorasani M, Musavi M, Mousavi M, Moossavi M, Khoddamian M, Sandoughi M, et al. Deoxyribonuclease I gene polymorphism and susceptibility to systemic lupus erythematosus. Clin Rheumatol. 2016;35(1):101-5. doi: 10.1007/s10067-015-3111-y. [PubMed: 26547219].
  • 7. Jahantigh D, Salimi S, Mousavi M, Moossavi M, Mohammadoo-Khorasani M, Narooei-nejad M, et al. Association Between Functional Polymorphisms of DNA Double-Strand Breaks in Repair Genes XRCC5, XRCC6 and XRCC7 with the Risk of Systemic Lupus Erythematosus in South East Iran. DNA Cell Biol. 2015;34(5):360-6. doi: 10.1089/dna.2014.2465. [PubMed: 25756210].
  • 8. Salimi S, Noora M, Nabizadeh S, Rezaei M, Shahraki H, Milad MK, et al. Association of the osteopontin rs1126616 polymorphism and a higher serum osteopontin level with lupus nephritis. Biomed Rep. 2016;4(3):355-60. doi: 10.3892/br.2016.589. [PubMed: 26998275]. [PubMed Central: PMC4774351].
  • 9. Horiuchi T, Washio M, Kiyohara C, Tsukamoto H, Tada Y, Asami T, et al. Combination of TNF-RII, CYP1A1 and GSTM1 polymorphisms and the risk of Japanese SLE: findings from the KYSS study. Rheumatology (Oxford). 2009;48(9):1045-9. doi: 10.1093/rheumatology/kep166. [PubMed: 19561157].
  • 10. Tobon GJ, Izquierdo JH, Canas CA. B lymphocytes: development, tolerance, and their role in autoimmunity—focus on systemic lupus erythematosus. Autoimmune Dis. 2013;2013.
  • 11. Ahearn JM, Liu CC, Kao AH, Manzi S. Biomarkers for systemic lupus erythematosus. Transl Res. 2012;159(4):326-42. doi: 10.1016/j.trsl.2012.01.021. [PubMed: 22424435].
  • 12. Tahernia L, Namazi S, Rezaei N, Ziaee V. Cytokines in systemic lupus erythematosus: their role in pathogenesis of disease and possible therapeutic opportunities. Rheumatol Res. 2017;2(1):1-9. doi: 10.22631/rr.2017.69997.1010.
  • 13. Mohammadoo-Khorasani M, Salimi S, Tabatabai E, Sandoughi M, Zakeri Z. Association of interleukin-1 receptor antagonist gene 86bp VNTR polymorphism with systemic lupus erythematosus in south east of Iran. Zahedan J Res Med Sci. 2013;16(12).
  • 14. Mohammadoo-Khorasani M, Salimi S, Tabatabai E, Sandoughi M, Zakeri Z, Farajian-Mashhadi F. Interleukin-1beta (IL-1beta) & IL-4 gene polymorphisms in patients with systemic lupus erythematosus (SLE) & their association with susceptibility to SLE. Indian J Med Res. 2016;143(5):591-6. doi: 10.4103/0971-5916.187107. [PubMed: 27488002]. [PubMed Central: PMC4989832].
  • 15. Talaat RM, Alrefaey SA, Bassyouni IH, Ashour ME, Raouf AA. Genetic polymorphisms of interleukin 6 and interleukin 10 in Egyptian patients with systemic lupus eythematosus. Lupus. 2016;25(3):255-64. doi: 10.1177/0961203315615219. [PubMed: 26568585].
  • 16. Jagodzinski PP, Piotrowski P, Olesinska M. Interleukin-7 receptor Thr244Ile gene polymorphism and the risk of systemic lupus erythematosus. J Med Sci. 2016;85(3):192. doi: 10.20883/jms.2016.123.
  • 17. Ahmed YM, Erfan DM, Hafez SF, Shehata IH, Morshedy NA. The association of single nucleotide polymorphism of interleukin-21 gene and serum interleukin-21 levels with systemic lupus erythematosus. Egypt J Med Human Gene. 2017;18(2):129-36. doi: 10.1016/j.ejmhg.2016.04.006.
  • 18. Lin J, Qin H, Wang Y, Liang J, Xu J. Analysis of interleukin 19 serum levels and single nucleotide polymorphisms in systemic lupus erythematosus. Gene Mol Res. 2016;15(2).
  • 19. Paradowska-Gorycka A, Sowinska A, Stypinska B, Grobelna MK, Walczyk M, Olesinska M, et al. Genetic Variants in IL-12B and IL-27 in the Polish Patients with Systemic Lupus Erythematosus. Scand J Immunol. 2016;84(1):49-60. doi: 10.1111/sji.12439. [PubMed: 27059274].
  • 20. Huang HT, Chen JM, Guo J, Lan Y, Wei YS. The association of interleukin-31 polymorphisms with interleukin-31 serum levels and risk of systemic lupus erythematosus. Rheumatol Int. 2016;36(6):799-805. doi: 10.1007/s00296-016-3422-6. [PubMed: 26769434].
  • 21. Wang Y, Zhou B, Zhao Y, Yu X, Liu Y, Zhang L. Association of Plasma IL-32 Levels and Gene Polymorphisms with Systemic Lupus Erythematosus in Chinese Han Population. Dis Markers. 2016;2016:2460206. doi: 10.1155/2016/2460206. [PubMed: 27069296]. [PubMed Central: PMC4789414].
  • 22. Su DL, Lu ZM, Shen MN, Li X, Sun LY. Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLE. J Biomed Biotechnol. 2012;2012:347141. doi: 10.1155/2012/347141. [PubMed: 22500087]. [PubMed Central: PMC3303597].
  • 23. Perl A. Systems biology of lupus: mapping the impact of genomic and environmental factors on gene expression signatures, cellular signaling, metabolic pathways, hormonal and cytokine imbalance, and selecting targets for treatment. Autoimmunity. 2010;43(1):32-47. doi: 10.3109/08916930903374774. [PubMed: 20001421]. [PubMed Central: PMC4020422].
  • 24. Tahmasebi Z, Akbarian M, Mirkazemi S, Shahlaee A, Alizadeh Z, Amirzargar AA, et al. Interleukin-1 gene cluster and IL-1 receptor polymorphisms in Iranian patients with systemic lupus erythematosus. Rheumatol Int. 2013;33(10):2591-6. doi: 10.1007/s00296-013-2784-2. [PubMed: 23722873].
  • 25. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006;2(11):619-26. doi: 10.1038/ncprheum0338. [PubMed: 17075601].
  • 26. Cash H, Relle M, Menke J, Brochhausen C, Jones SA, Topley N, et al. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J Rheumatol. 2010;37(1):60-70. doi: 10.3899/jrheum.090194. [PubMed: 19955044].
  • 27. Sarra M, Monteleone G. Interleukin-21: a new mediator of inflammation in systemic lupus erythematosus. J Biomed Biotechnol. 2010;2010:294582. doi: 10.1155/2010/294582. [PubMed: 20652041]. [PubMed Central: PMC2905909].
  • 28. Ding L, Wang S, Chen GM, Leng RX, Pan HF, Ye DQ. A single nucleotide polymorphism of IL-21 gene is associated with systemic lupus erythematosus in a Chinese population. Inflammation. 2012;35(6):1781-5. doi: 10.1007/s10753-012-9497-7. [PubMed: 22752563].
  • 29. Leng RX, Wang W, Cen H, Zhou M, Feng CC, Zhu Y, et al. Gene-gene and gene-sex epistatic interactions of MiR146a, IRF5, IKZF1, ETS1 and IL21 in systemic lupus erythematosus. PLoS One. 2012;7(12). e51090. doi: 10.1371/journal.pone.0051090. [PubMed: 23236436]. [PubMed Central: PMC3517573].
  • 30. Lan Y, Luo B, Wang JL, Jiang YW, Wei YS. The association of interleukin-21 polymorphisms with interleukin-21 serum levels and risk of systemic lupus erythematosus. Gene. 2014;538(1):94-8. doi: 10.1016/j.gene.2014.01.012. [PubMed: 24434811].
  • 31. Webb R, Merrill JT, Kelly JA, Sestak A, Kaufman KM, Langefeld CD, et al. A polymorphism within IL21R confers risk for systemic lupus erythematosus. Arthritis Rheum. 2009;60(8):2402-7. doi: 10.1002/art.24658. [PubMed: 19644854]. [PubMed Central: PMC2782592].
  • 32. Yap DY, Lai KN. The role of cytokines in the pathogenesis of systemic lupus erythematosus - from bench to bedside. Nephrology (Carlton). 2013;18(4):243-55. doi: 10.1111/nep.12047. [PubMed: 23452295].
  • 33. Wong CK, Ho CY, Li EK, Tam LS, Lam CW. Elevated production of interleukin-18 is associated with renal disease in patients with systemic lupus erythematosus. Clin Exp Immunol. 2002;130(2):345-51. [PubMed: 12390326]. [PubMed Central: PMC1906516].
  • 34. Amerio P, Frezzolini A, Abeni D, Teofoli P, Girardelli CR, De Pita O, et al. Increased IL-18 in patients with systemic lupus erythematosus: relations with Th-1, Th-2, pro-inflammatory cytokines and disease activity. IL-18 is a marker of disease activity but does not correlate with pro-inflammatory cytokines. Clin Exp Rheumatol. 2002;20(4):535-8. [PubMed: 12175109].
  • 35. Calvani N, Richards HB, Tucci M, Pannarale G, Silvestris F. Up-regulation of IL-18 and predominance of a Th1 immune response is a hallmark of lupus nephritis. Clin Exp Immunol. 2004;138(1):171-8. doi: 10.1111/j.1365-2249.2004.02588.x. [PubMed: 15373921]. [PubMed Central: PMC1809179].
  • 36. Wang D, Drenker M, Eiz-Vesper B, Werfel T, Wittmann M. Evidence for a pathogenetic role of interleukin-18 in cutaneous lupus erythematosus. Arthritis Rheum. 2008;58(10):3205-15. doi: 10.1002/art.23868. [PubMed: 18821674].
  • 37. Sutton CE, Mielke LA, Mills KH. IL-17-producing gammadelta T cells and innate lymphoid cells. Eur J Immunol. 2012;42(9):2221-31. doi: 10.1002/eji.201242569. [PubMed: 22949320].
  • 38. Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, Yalavarthi S, et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011;187(1):490-500. doi: 10.4049/jimmunol.1100123. [PubMed: 21606249]. [PubMed Central: PMC3119764].
  • 39. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987-97. doi: 10.1016/S0140-6736(08)60453-5. [PubMed: 18358926].
  • 40. Crispin JC, Oukka M, Bayliss G, Cohen RA, Van Beek CA, Stillman IE, et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol. 2008;181(12):8761-6. [PubMed: 19050297]. [PubMed Central: PMC2596652].
  • 41. Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X, et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 2009;60(5):1472-83. doi: 10.1002/art.24499. [PubMed: 19404966].
  • 42. Sabat R. IL-10 family of cytokines. Cytokine Growth Factor Rev. 2010;21(5):315-24. doi: 10.1016/j.cytogfr.2010.11.001. [PubMed: 21112807].
  • 43. Okamoto A, Fujio K, Okamura T, Yamamoto K. Regulatory T-cell-associated cytokines in systemic lupus erythematosus. J Biomed Biotechnol. 2011;2011:463412. doi: 10.1155/2011/463412. [PubMed: 22219657]. [PubMed Central: PMC3247013].
  • 44. Lin PW, Huang CM, Huang CC, Tsai CH, Tsai JJ, Chang CP, et al. The association of -627 interleukin-10 promoter polymorphism in Chinese patients with systemic lupus erythematosus. Clin Rheumatol. 2007;26(3):298-301. doi: 10.1007/s10067-006-0329-8. [PubMed: 16826368].
  • 45. Sobkowiak A, Lianeri M, Wudarski M, Lacki JK, Jagodzinski PP. Genetic variation in the interleukin-10 gene promoter in Polish patients with systemic lupus erythematosus. Rheumatol Int. 2009;29(8):921-5. doi: 10.1007/s00296-008-0776-4. [PubMed: 19082598].
  • 46. Lin YJ, Wan L, Huang CM, Sheu JJ, Chen SY, Lin TH, et al. IL-10 and TNF-alpha promoter polymorphisms in susceptibility to systemic lupus erythematosus in Taiwan. Clin Exp Rheumatol. 2010;28(3):318-24. [PubMed: 20576226].
  • 47. Rezaei A, Ziaee V, Sharabian FT, Harsini S, Mahmoudi M, Soltani S, et al. Lack of association between interleukin-10, transforming growth factor-beta gene polymorphisms and juvenile-onset systemic lupus erythematosus. Clin Rheumatol. 2015;34(6):1059-64. doi: 10.1007/s10067-015-2877-2. [PubMed: 25633651].
  • 48. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62(2):542-52. doi: 10.1002/art.27221. [PubMed: 20112381]. [PubMed Central: PMC3057537].
  • 49. Pereira VA, Sanchez-Arcila JC, Teva A, Perce-da-Silva DS, Vasconcelos MP, Lima CA, et al. IL10A genotypic association with decreased IL-10 circulating levels in malaria infected individuals from endemic area of the Brazilian Amazon. Malar J. 2015;14:30. doi: 10.1186/s12936-015-0548-z. [PubMed: 25627396]. [PubMed Central: PMC4334410].
  • 50. Salimi S, Mohammadoo-Khorasani M, Yaghmaei M, Mokhtari M, Moossavi M. Possible association of IL-4 VNTR polymorphism with susceptibility to preeclampsia. Biomed Res Int. 2014;2014:497031. doi: 10.1155/2014/497031. [PubMed: 24877103]. [PubMed Central: PMC4020502].
  • 51. Mahmoudi M, Tahghighi F, Ziaee V, Harsini S, Rezaei A, Soltani S, et al. Interleukin-4 single nucleotide polymorphisms in juvenile systemic lupus erythematosus. Int J Immunogenet. 2014;41(6):512-7. doi: 10.1111/iji.12152. [PubMed: 25320043].
  • 52. Yu HH, Liu PH, Lin YC, Chen WJ, Lee JH, Wang LC, et al. Interleukin 4 and STAT6 gene polymorphisms are associated with systemic lupus erythematosus in Chinese patients. Lupus. 2010;19(10):1219-28. doi: 10.1177/0961203310371152. [PubMed: 20530519].
  • 53. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87(6):2095-147. [PubMed: 8630372].
  • 54. Suzuki H, Takemura H, Kashiwagi H. Interleukin-1 receptor antagonist in patients with active systemic lupus erythematosus. Enhanced production by monocytes and correlation with disease activity. Arthritis Rheum. 1995;38(8):1055-9. [PubMed: 7639800].
  • 55. Salimi S, Mohammadoo-Khorasani M, Mousavi M, Yaghmaei M, Mokhtari M, Farajian-Mashhadi F. Association of interleukin-1 receptor antagonist VNTR polymorphism and risk of pre-eclampsia in southeast Iranian population. J Obstet Gynaecol Res. 2016;42(2):142-7. doi: 10.1111/jog.12865. [PubMed: 26555681].
  • 56. Rus V, Atamas SP, Shustova V, Luzina IG, Selaru F, Magder LS, et al. Expression of cytokine- and chemokine-related genes in peripheral blood mononuclear cells from lupus patients by cDNA array. Clin Immunol. 2002;102(3):283-90. doi: 10.1006/clim.2001.5182. [PubMed: 11890715].
  • 57. Tayal V, Kalra BS. Cytokines and anti-cytokines as therapeutics--an update. Eur J Pharmacol. 2008;579(1-3):1-12. doi: 10.1016/j.ejphar.2007.10.049. [PubMed: 18021769].
  • 58. Scuderi F, Convertino R, Molino N, Provenzano C, Marino M, Zoli A, et al. Effect of pro-inflammatory/anti-inflammatory agents on cytokine secretion by peripheral blood mononuclear cells in rheumatoid arthritis and systemic lupus erythematosus. Autoimmunity. 2003;36(2):71-7. [PubMed: 12820688].
  • 59. Parks CG, Pandey JP, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS, et al. Genetic polymorphisms in tumor necrosis factor (TNF)-alpha and TNF-beta in a population-based study of systemic lupus erythematosus: associations and interaction with the interleukin-1alpha-889 C/T polymorphism. Hum Immunol. 2004;65(6):622-31. doi: 10.1016/j.humimm.2004.03.001. [PubMed: 15219382].
  • 60. Chua KH, Lau TP, Tee ZY, Tan SY, Lian LH. Genetic Polymorphisms of the Interleukin-1 beta (IL-1β) -511 and +3954 Single Nucleotide Polymorphisms (SNPs) in Malaysian Systemic Lupus Erythematosus (SLE) Patients. J Health Sci. 2009;55(4):657-62. doi: 10.1248/jhs.55.657.
  • 61. Yu MC, Huang CM, Wu MC, Wu JY, Tsai FJ. Association of TAP2 gene polymorphisms in Chinese patients with rheumatoid arthritis. Clin Rheumatol. 2004;23(1):35-9. doi: 10.1007/s10067-003-0769-3. [PubMed: 14749980].
  • 62. Huang CM, Wu MC, Wu JY, Tsai FJ. Lack of association of interleukin-1ß gene polymorphisms in Chinese patients with systemic lupus erythematosus. Rheumatol Int. 2002;21(5):173-5. doi: 10.1007/s00296-001-0164-9.
  • 63. Camargo JF, Correa PA, Castiblanco J, Anaya JM. Interleukin-1beta polymorphisms in Colombian patients with autoimmune rheumatic diseases. Genes Immun. 2004;5(8):609-14. doi: 10.1038/sj.gene.6364133. [PubMed: 15470475].
  • 64. Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Steinkasserer A, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet. 1993;91(4):403-4. [PubMed: 8500797].
  • 65. Blakemore AI, Tarlow JK, Cork MJ, Gordon C, Emery P, Duff GW. Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum. 1994;37(9):1380-5. [PubMed: 7945503].
  • 66. Chai HC, Phipps ME, Chua KH. Genetic risk factors of systemic lupus erythematosus in the Malaysian population: a minireview. Clin Dev Immunol. 2012;2012:963730. doi: 10.1155/2012/963730. [PubMed: 21941582]. [PubMed Central: PMC3176625].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments